Sort   by:  
 Page size 
TranscriptomicsBiopsies from metastatic Clear Cell Renal Carcinoma before or after treatment with nivolumab
Tumor core needle biopsies from kidney or metastatic sites obtained at trial enrollment i.e. Screen and/or at Cycle 2 Day 8 (i.e.Week 4) from metastatic clear cell RCC patients treated with 0.2mpk, 3mpk or 10mpk (as 2nd or further line of therapy; Arms A,B,C) or 10mpk (as first line therapy; Arm D) ...
ORGANISM(S): Homo sapiens 
2016-05-15 | E-MTAB-3218 | biostudies-arrayexpress
TranscriptomicsBlood RNA from metastatic Clear Cell Renal Carcinoma patients before or after treatment with nivolumab
Blood samples obtained at Cycle 1 Day 1, Cycle 1 Day 2 or at Cycle 2 Day 8 (i.e. before treatment, 24 hours after treatment or Week 4) from metastatic clear cell RCC patients treated with 0.2mpk, 3mpk or 10mpk (as 2nd or further line of therapy; Arms A,B,C) or 10mpk (as first line therapy; Arm D) of...
ORGANISM(S): Homo sapiens 
2016-05-15 | E-MTAB-3219 | biostudies-arrayexpress
TranscriptomicsBiopsies from advanced melanoma before and/or after treatment with nivolumab
Expression profiling of tumor samples obtained during CA209-038 (ClinicalTrials.gov Identifier: NCT01621490). The purpose of this study is to evaluate pharmacodynamic changes of nivolumab and nivolumab in combination with ipilimumab treatment on the biomarkers measured in the peripheral blood and tu...
ORGANISM(S): Homo sapiens 
2022-01-01 | E-MTAB-4030 | biostudies-arrayexpress
TranscriptomicsSingle cell RNA-seq of Panc02-H7-Fluc model with vehicle tobemstomig, nivolumab and relatlimab-like treatment
We used transgenic mice challenged subcutaneously with Panc02-H7-Fluc tumors to compare the efficacy of tobemstomig with nivolumab and relatlimab-like monotherapies, as well as their combination, and further investigated their mechanism of action. We used a murinized version of tobemstomig, nivoluma...
ORGANISM(S): Mus musculus 
2025-11-27 | E-MTAB-15144 | biostudies-arrayexpress
GenomicsNext Generation Sequencing Facilitates Quantitative Analysis of tumor samples from HCC patients receiving Nivolumab.
Next Generation Sequencing Facilitates Quantitative Analysis of tumor samples from HCC patients receiving Nivolumab.
PRJNA906102 | ENA
GenomicsNCTN: A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study) (S1400I)
NCTN: A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study) (S1400I)
PRJNA1307670 | ENA
GenomicsNCTN: A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study) (S1400I)
NCTN: A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study) (S1400I)
PRJNA1307671 | ENA
GenomicsCorrelative study in Protocol S1400I A PHASE III RANDOMIZED STUDY OF NIVOLUMAB PLUS IPILIMUMAB VERSUS NIVOLUMAB IN STAGE IV SQUAMOUS CELL LUNG CANCER (CIMAC-CIDC)
Correlative study in Protocol S1400I A PHASE III RANDOMIZED STUDY OF NIVOLUMAB PLUS IPILIMUMAB VERSUS NIVOLUMAB IN STAGE IV SQUAMOUS CELL LUNG CANCER (CIMAC-CIDC)
PRJNA1014196 | ENA
GenomicsCorrelative study in Protocol S1400I A PHASE III RANDOMIZED STUDY OF NIVOLUMAB PLUS IPILIMUMAB VERSUS NIVOLUMAB IN STAGE IV SQUAMOUS CELL LUNG CANCER (CIMAC-CIDC)
Correlative study in Protocol S1400I A PHASE III RANDOMIZED STUDY OF NIVOLUMAB PLUS IPILIMUMAB VERSUS NIVOLUMAB IN STAGE IV SQUAMOUS CELL LUNG CANCER (CIMAC-CIDC)
PRJNA1014197 | ENA
GenomicsImmunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma
Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma
PRJNA1027897 | ENA
Sort   by:  
 Page size